What is happening, in plain language.
Aniket has a condition called Familial Cerebral Cavernous Malformation Syndrome (FCCM). His brain contains many clusters of abnormal, thin-walled blood vessels known as cavernomas. Most are small and quiet. Two are large enough to cause symptoms. One of them, in the right thalamus, is the principal concern.
The Dominant Lesion
A 2.8 cm cavernoma in the right anterior thalamus, with recent or subacute bleeding inside it, pressing on the midbrain and third ventricle.
The Second Lesion
A 1.5 cm cavernoma in the left anterior cingulate gyrus, adjacent to the corpus callosum, with mild mass effect.
Background Lesions
18 to 24 additional cavernomas scattered across both hemispheres, pons, cerebellum, and a tiny one in the spinal cord at D5. Most are silent.
Aniket is currently able to walk. He has giddiness, imbalance, progressive memory loss, spatial disorientation, impaired executive function, and headaches. A recent seizure episode was reported. The neurologist at Sir H.N. Reliance Hospital (Dr. Arun Shah, 10 April 2026) has advised anti-edema measures, low-dose steroid, and an anti-epileptic drug, with a plain CT to observe for fresh bleeding. This is a reasonable bridging plan while a definitive surgical opinion is obtained.
The question that matters
Should the dominant thalamic cavernoma be surgically removed now, or observed? The honest answer is that this is exactly the kind of case where the opinion of a very high-volume cavernoma surgeon changes outcomes. The thalamus is deep, eloquent territory. A general neurosurgeon should not operate here. A surgeon who has personally resected hundreds of deep cavernomas should.
Familial Cerebral Cavernous Malformation Syndrome.
A cavernoma is a cluster of abnormal, dilated capillaries without normal brain tissue between them. The walls are fragile and leak small amounts of blood over time. Around 40 to 60 percent of people with cavernomas have the familial form, which is inherited in an autosomal dominant pattern. Familial disease is defined by multiple lesions, a family history, or a confirmed mutation in one of three genes: KRIT1 (CCM1), CCM2, or PDCD10 (CCM3).
The PET-CT report from Dr. Solav's Spectlab specifically flags this: "Rule out Familial Cerebral Cavernous Malformation Syndrome (FCCM)." The imaging pattern, with more than 18 lesions across multiple brain regions plus a spinal cord lesion, is essentially diagnostic of the familial form. Genetic testing would confirm which of the three genes is involved. CCM3 mutations, in particular, tend to behave more aggressively and warrant extra vigilance.
On the PET-CT comment about Alzheimer's disease
The Spectlab report notes a "neurodegenerative pattern suggestive of Alzheimer's disease, differential vascular dementia." This wording deserves caution. FDG-PET hypometabolism in someone with multiple bleeding cavernomas, active seizures, recent edema, and steroid use is far more likely to reflect cavernoma-related cortical dysfunction and vascular injury than Alzheimer's. At age 46, with structural lesions that fully explain his cognitive symptoms, the right framing is cognitive impairment secondary to FCCM. A formal Alzheimer's label should not be accepted without CSF biomarkers or amyloid PET, and should not be assumed in the presence of this much structural disease.
HIV and VDRL are negative. Thyroid function is normal. Liver enzymes are only very marginally elevated (SGPT 48.8, GGT 42.5) and not a barrier to surgery. Calcium and phosphorus are at the upper end of normal but within range. There is no midline shift and no brain herniation on the most recent CT. He is ambulatory.
What the scans actually show.
Dominant right anterior thalamic cavernoma
Approximately 2.5 × 2.8 × 2.0 cm. Hyperdense core on CT suggesting recent or subacute hemorrhagic component. Zabramski type 2 on MRI, meaning a mixed-age hemorrhage with a hemosiderin rim. Moderate mass effect with compression of adjacent thalamic tissue and mild indentation of the superior midbrain. Extends toward the hypothalamus, third ventricular anterior recess, right internal capsule, and basal ganglia. Abuts both ICA bifurcations and the A1 segments of the ACA. No herniation.
Left anterior cingulate gyrus cavernoma
Approximately 1.0 × 1.5 cm. Well-defined, mildly lobulated, hyperdense with chronic hemorrhagic components. Adjacent to the genu of the corpus callosum. Minimal local mass effect. Zabramski type 2.
Multiple smaller cavernomas
Scattered through the left fronto-parietal white matter, posterior periventricular regions, left corona radiata, left centrum semiovale, right basal ganglia, corpus callosum, pons, and right cerebellum. Size range 5 mm to 1.2 cm. Most are Zabramski type 3 or 4 and non-enhancing. A tiny cavernoma is also noted in the spinal cord at D5 with no cord compression or edema.
Intraventricular hemorrhage
Hyperdense material in the dependent portions of bilateral occipital horns, density 40 to 60 HU. This is consistent with small-volume IVH, most likely tracked from the dominant thalamic lesion. No hydrocephalus at present, but this warrants short-interval monitoring.
Adrenal lesions on PET-CT
Multiple bilateral ametabolic adrenal lesions. Right: medial limb 8 mm, lateral limb 20 × 6 mm. Left: medial limb 15 mm, another 11 mm calcific, root 6 mm, lateral limb 8 mm. On MRI, T2 hyperintense with restriction in one on the right. FDG-negative behaviour suggests benign adenomas rather than metastases, but bilateral multifocal adrenal lesions in a patient with a vascular malformation syndrome should prompt endocrine workup (plasma metanephrines, aldosterone/renin, overnight dexamethasone suppression) to exclude pheochromocytoma and functional adenoma before any brain surgery under anesthesia.
What can actually be done.
There are three internationally recognised management strategies for cavernomas. The choice depends on lesion location, symptom severity, and bleed history. For Aniket, the most important decisions concern the dominant thalamic lesion. The smaller lesions are managed conservatively.
Open craniotomy with microsurgical removal of the lesion. International guidelines recommend surgical removal for symptomatic lesions that have bled, produce mass effect, or cause intractable seizures. For a 2.8 cm thalamic cavernoma that has bled and is causing cognitive and balance symptoms, resection is the option most likely to prevent a catastrophic re-bleed.
Why it matters here: the thalamus is deep and eloquent. Outcomes depend almost entirely on the surgeon. In high-volume hands, deep cavernomas can be removed with acceptable morbidity. In low-volume hands, the risk is unacceptable. Surgeons such as Michael Lawton have personally resected more than 1,400 cavernous malformations, including more than 400 in the brainstem and other delicate areas.
Approach options: anterior interhemispheric transcallosal, anterior contralateral transcallosal transchoroidal, or anterior transcortical transventricular, chosen based on the exact lesion trajectory on tractography.
Serial MRI with susceptibility-weighted imaging every 6 to 12 months. Symptomatic management of seizures with anti-epileptic drugs. Headache management. Rehabilitation. This is the correct approach for the 18+ smaller, silent lesions. It is not the right approach for the dominant thalamic lesion given its size, recent bleeding, mass effect, and symptoms.
The 2017 Angioma Alliance consensus guidelines explicitly state that radiosurgery is not recommended in familial CCM, because radiation is associated with formation of new cavernomas. This removes gamma knife from serious consideration for Aniket. It could, in very specific cases, be debated for a single inaccessible lesion, but not as a general strategy in familial disease.
A minimally invasive laser ablation guided by MRI, performed through a tiny skull opening. Early single-institution series show benefit for lesions causing epilepsy. Evidence for deep thalamic lesions is still limited. Worth asking about as a backup option, particularly at centres like Duke, Cleveland Clinic, or Texas Children's that have active LITT programmes.
Anti-epileptic drugs for seizure control (already started). Short-course low-dose steroids for edema (already started). Headache prophylaxis. Propranolol is under investigation and has led to partial regression in select cases, but evidence remains preliminary. Several trials of statins and Rho-kinase inhibitors are ongoing. Nothing here replaces surgery for the dominant lesion, but these can be discussed with the treating team.
1. Stabilise on AEDs and low-dose steroids. 2. Complete adrenal workup (metanephrines, dexamethasone suppression) before any general anesthesia. 3. Obtain genetic testing for KRIT1, CCM2, PDCD10. 4. Obtain two independent high-volume surgical opinions on the thalamic lesion (one international if feasible). 5. Proceed with microsurgical resection at the highest-volume centre the family can reach. 6. Annual SWI-MRI surveillance of remaining lesions lifelong.
Where to be treated.
Volume matters enormously in cavernoma surgery. A surgeon who does two deep cavernomas a year produces different outcomes from one who does fifty. The names below are selected on that basis: personal cavernoma volume, published outcomes, and formal Centre of Excellence recognition.
International, first tier
India, first tier
Best single action: request a remote second opinion from Barrow (Dr. Lawton's team). Barrow routinely reviews imaging sent from overseas and provides a written opinion before any travel decision. This costs a few hundred dollars and settles the question of whether surgery is advised, what approach, and what the expected risk profile is. If surgery is then recommended, the family can decide between travelling to Barrow or using that report as the gold-standard reference to discuss with Dr. Misra in Mumbai.
What treatment is likely to cost.
Costs vary by institution, complexity, length of ICU stay, and rehabilitation needs. The figures below are indicative ranges for the microsurgical resection of a deep cavernoma, based on published estimates from medical tourism sources and institutional data current to early 2026. These are rough estimates, not quotes. Every centre will quote formally after reviewing imaging.
| Location | Centre Type | Surgery Cost Range | Total Incl. Stay |
|---|---|---|---|
| USA (Barrow, Duke, Penn, Stanford) | Top-tier academic | USD 80,000 – 200,000 | USD 150,000 – 300,000+ |
| Germany (Charité, Munich) | Academic centre | EUR 40,000 – 80,000 | EUR 60,000 – 120,000 |
| UK (NHS private wing) | Academic / private | GBP 35,000 – 70,000 | GBP 60,000 – 110,000 |
| Singapore / Thailand | JCI-accredited private | USD 25,000 – 55,000 | USD 40,000 – 80,000 |
| India (Hinduja, Jaslok, Apollo, Fortis) | Private tertiary | INR 5,00,000 – 15,00,000 | INR 8,00,000 – 25,00,000 |
| India (AIIMS, NIMHANS) | Public apex | INR 50,000 – 3,00,000 | INR 1,00,000 – 5,00,000 |
Additional costs to budget for
- Pre-operative adrenal workup, genetic testing, and functional MRI / tractography: INR 50,000 to 2,00,000 in India, USD 3,000 to 8,000 in USA.
- Post-operative ICU and hospital stay: typically 7 to 14 days for deep cavernoma surgery, already included in the ranges above at most centres.
- Neurorehabilitation (physiotherapy, occupational therapy, cognitive rehab): 3 to 6 months, INR 1,00,000 to 4,00,000 in India, USD 15,000 to 40,000 in USA.
- Lifelong annual SWI-MRI surveillance: INR 8,000 to 15,000 per scan in India.
- Travel, visa, and accommodation for international treatment: USD 5,000 to 15,000 for the patient plus one attendant over 4 to 6 weeks.
- Remote second opinion consultation (Barrow, Mayo, Cleveland Clinic): USD 500 to 1,500.
For a 2.8 cm thalamic cavernoma that has bled, the cost differential between India and the USA is large, but the surgeon matters more than the country. A superb Indian cerebrovascular surgeon in Mumbai will produce better outcomes than a merely average American academic surgeon. The optimal path for most families is: obtain the US remote opinion for the plan, execute the surgery in India with a top-tier vascular neurosurgeon. This combines the highest-quality planning with the most sustainable cost.
What the family should do this week, next month, and beyond.
Stabilise and consolidate
Continue AEDs and low-dose steroids as prescribed by Dr. Arun Shah. Avoid any blood thinners, aspirin, or NSAIDs unless specifically cleared. Request full DICOM MRI and CT files on DVD or cloud link from Sahyadri and Lokmanya hospitals, plus the PET-CT. Compile all reports into a single PDF pack.
Complete essential pre-surgical workup
Endocrine evaluation for the bilateral adrenal lesions: plasma metanephrines, 24-hour urinary metanephrines, aldosterone-renin ratio, overnight dexamethasone suppression test. This is non-negotiable before any brain surgery under general anesthesia. Arrange genetic testing for KRIT1, CCM2, PDCD10 through a medical geneticist (Centre for Human Genetics Bengaluru, MedGenome, or Sahyadri genetic services).
Secure expert opinions
Submit imaging and reports for remote review to Barrow Neurological Institute (international patient services, Phoenix, Arizona). Simultaneously book an in-person consultation with Dr. Basant K. Misra at Hinduja Hospital, Mumbai. A third opinion at NIMHANS, Bengaluru, is worth considering. Do not proceed with surgery at any centre whose surgeon does fewer than 20 to 30 deep cavernomas per year.
Plan and execute definitive treatment
Based on combined opinions, choose the surgical centre. Arrange functional MRI and diffusion tensor imaging (tractography) at the chosen centre for approach planning. Schedule surgery. Plan for 10 to 14 days hospital stay and 3 to 6 months of structured rehabilitation. Arrange a primary caregiver and financial planning for rehabilitation costs.
Surveillance and family screening
Annual SWI-MRI for life. Cognitive rehabilitation and periodic neuropsychological assessment. Screen first-degree relatives (parents, siblings, children) with a single SWI-MRI of the brain, since FCCM is autosomal dominant. Connect with the Alliance to Cure Cavernous Malformation (alliancetocure.org) and the Cavernoma Alliance UK for peer support, registry enrolment, and trial opportunities.